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ABSTRACT 
The effects of trimetazidine, a novel anti-ischemic agent, on the development of oxidative 
stress induced in mice with lipopolysaccharide endotoxin were investigated. The drug was 
administered orally once daily at doses of 1.8, 3.6 or 7.2 mg/kg for two days prior to intraperi-
toneal (i.p.) injection of lipopolysaccharide E (200 µg/kg) and at time of endotoxin admini-
stration. Mice were euthanized 4 h after administration of the lipopolysaccharide. Lipid per-
oxidation (malondialdehyde; MDA), reduced glutathione (GSH) and nitric oxide (ni-
trite/nitrate) concentrations were measured in brain and liver. The administration of lipopoly-
saccharide increased oxidative stress in both the brain and liver tissue. MDA increased by 
33.9 and 107.1 %, GSH decreased by 23.9 and 84.3 % and nitric oxide increased 70.3 and 
48.4 % in the brain and liver, respectively. Compared with the lipopolysaccharide control 
group, brain MDA decreased by 26.2 and 36.7 %, while GSH increased by 18.2 and 25.8 % 
after the administration of trimetazidine at 3.6 and 7.2 mg/kg, respectively. Brain nitric oxide 
decreased by 45.3, 50.8 and 57.0 % by trimetazidine at 1.8, 3.6 and 7.2 mg/kg, respectively. 
In the liver, MDA decreased by 18.7, 30.7 and 49.4 % and GSH increased by 150.3, 204.8 
and 335.4 % following trimetazidine administration at 1.8, 3.6 and 7.2 mg/kg. Meanwhile, 
nitric oxide decreased by 17.3 % by 7.2 mg/kg of trimetazidine. These results indicate that 
administration of trimetazidine in the presence of mild systemic inflammatory response alle-
viates oxidative stress in the brain and liver. 
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INTRODUCTION 
Trimetazidine, is an antianginal agent 
with unique properties. Trimetazidine does 
not affect systolic blood pressure, coronary 
blood flow or heart rate (McClellan and 
Plosker, 1999). The drug is a partial fatty-
acid-oxidation inhibitor that selectively in-
hibits long-chain 3-ketoacyl coenzyme A 
thiolase (the last enzyme involved in β-
oxidation), shifting energy substrate prefer-
ence from free fatty-acid metabolism to-
wards glucose oxidation, which reduces 
oxygen demands and improves myocardial 
efficiency (Kantor et al., 2000; Fragasso et 
al., 2009). By optimizing energy metabo-
lism, the drug proved of value in reducing 
the frequency of anginal symptoms (Cross, 
2001) and may improve left ventricular 
function in patients with heart failure (Fra-
gasso et al., 2006). Trimetazidine preserves 
cardiac mitochondrial function, thereby re-
ducing the formation of oxidative damage 
(Baumert et al., 2004). In this sense, the 
drug represents a novel approach for the 
management of ischemic heart disease and 
EXCLI Journal 2011;10:162-172 – ISSN 1611-2156 
Received: September 06, 2011, accepted: October 03, 2011, published: October 10, 2011 
 
163 
terms such as metabolic modulator or cyto-
protective has been used to describe its ac-
tion (Desideri and Celegon, 1998; Belardi-
nelli, 2000; Cross, 2001). Studies have 
shown that trimetazidine exerts cytoprotec-
tive effects under conditions of ischemia in 
different organs such as the heart (Poloski 
et al., 2002; Lopaschuk et al., 2003), lung 
(Inci et al., 2001), kidney (Faure et al., 
2004; Jayle et al., 2007), intestine (Tetik et 
al., 1999; Kuralay et al., 2003), brain (Iqbal 
et al., 2002) and liver (Settaf et al., 1999). 
Trimetazidine displays a number of impor-
tant pharmacological effects. The drug ex-
hibited neuroprotective activity in retina 
subjected to ischemia by inhibiting ex-
tracellular glutamate accumulation (Payet et 
al., 2004). It showed marked antinocicep-
tive effects in acute pain models, anti-
oedematogenic, antidepressive as well as 
gastric protective properties (Abdel-Salam 
and El-Batran, 2005). The drug also less-
ened the development of hepatic damage 
due to carbon tetrachloride in rats (Abdel-
Salam et al., 2005).  
Bacterial lipopolysaccharide is used 
widely in experimental animals to study the 
effect of inflammatory stimuli on organ 
functions. Systemic administration of 
lipopolysaccharide E has been shown to 
impair antioxidant mechanisms, induce 
lipid peroxidation and impairment in mito-
chondrial redox activity (Noble et al., 2007; 
Jacewicz et al., 2009) and causes brain in-
flammation (Jeong et al., 2010) as well as 
neuronal damage (Qin et al.. 2007). The 
present study therefore aimed to investigate 
the effect of the metabolic modulator 
trimetazidine on the oxidative stress in the 
brain and liver after the administration of 
bacterial lipopolysaccharide in mice.  
 
MATERIAL AND METHODS 
Animals 
Swiss male albino mice 20-22 g of body 
weight (age: 5-6 weeks) were used. Mice 
were obtained from animal house colony of 
the National Research Centre (Cairo, 
Egypt). Standard laboratory food and water 
were provided ad libitum. Animal proce-
dures were performed in accordance with 
the Ethics Committee of the National Re-
search Centre and followed the recommen-
dations of the National Institutes of Health 
Guide for Care and Use of Laboratory 
Animals (Publication No. 85-23, revised 
1985). Equal groups of 6 mice each were 
used in all experiments.  
 
Drugs and chemicals 
Lipopolysaccharide derived from  
Escherichia coli (Serotype 055: B5, Sigma, 
St Louis, MO, USA) was used and dis-
solved in sterile saline, aliquoted, and fro-
zen at −20 °C. Trimetazidine (Amrya 
Pharm. Ind., Cairo, Egypt) was used and 
dissolved in isotonic (0.9 % NaCl) saline 
solution immediately before use. The doses 
of trimetazidine in the study were based 
upon the human dose after conversion to 
that of rat according to Paget and Barnes 
(1964) conversion tables.  
 
Study design 
Mice were randomly divided into 5 
equal groups (6 mice each). Mice were 
treated with saline (group 1), trimetazidine 
(groups 2, 3, 4) once daily orally for 2 days 
before the administration of lipopoly-
saccharide and at time of endotoxin admini-
stration (200 mg/kg, i.p.). In addition, a 
fifth group (n = 6) received only saline (-ve 
control). Mice were euthanized 4 h after 
lipopolysaccharide injection by decapitation 
under ether anaesthesia, brains and livers 
were then removed, washed with ice-cold 
saline solution (0.9 % NaCl), weighed and 
stored at -80 ºC for the biochemical analy-
ses. The tissues were homogenized with 
0.1 M phosphate buffer saline at pH 7.4, to 
give a final concentration of 10 % w/v for 
the biochemical assays.  
 
Determination of lipid peroxidation 
Lipid peroxidation was assayed by 
measuring the level of malondialdehyde 
(MDA). Malondialdehyde forms a 1:2 ad-
duct with thiobarbituric acid which can be 
measured by spectrophotometry. Malondi-
aldehyde was determined by measuring 
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thiobarbituric reactive species using the 
method of Ruiz-Larrea et al. (1994), in 
which the thiobarbituric acid reactive sub-
stances react with thiobarbituric acid to pro-
duce a red colored complex having peak 
absorbance at 532 nm. 
 
Determination of reduced glutathione  
Reduced glutathione (GSH) was deter-
mined by Ellman's method (1959). The pro-
cedure is based on the reduction of Ell-
man´s reagent by –SH groups of GSH to 
form 2-nitro-s-mercaptobenzoic acid. The 
nitromercaptobenzoic acid anion has an in-
tense yellow color which can be determined 
spectrophotometrically.  
 
Determination of nitric oxide  
Nitric oxide measured as nitrite was de-
termined by using Griess reagent, according 
to the method of Moshage et al. (1995) 
where nitrite, stable end product of nitric 
oxide radical, is mostly used as indicator 
for the production of nitric oxide.  
 
Statistical analysis 
Data are expressed as mean ± SEM. The 
data were analyzed by one way ANOVA 
followed by Duncan’s multiple range test, 
using SPSS software (SAS Institute Inc., 
Cary, NC). A probability value of less than 
0.05 was considered statistically significant.  
 
RESULTS 
Effect of trimetazidine on brain oxidative 
stress 
The administration of lipopolysaccha-
ride significantly increased brain MDA by 
33.9 % (22.53 ± 1.30 vs 16.82 ± 
0.90 nmol/g, p<0.05). GSH decreased by 
23.9 % (3.02 ± 0.18 vs 3.97 ± 0.22 µmol/g, 
p<0.05), while nitric oxide increased by 
70.3 % (47.70 ± 3.10 vs 28.00 ± 
1.70 µmol/g, p<0.05) after lipopolysaccha-
ride injection compared with the saline con-
trol group. Brain MDA was not signifi-
cantly altered by treatment with trimetazi-
dine at 1.8 mg/kg. However, MDA de-
creased by 26.2 and 36.7 % after trimetazi-
dine at 3.6 and 7.2 mg/kg, respectively 
(16.63 ± 0.70 and 14.27 ± 0.80 vs 22.53 ± 
1.30 nmol/g) (Figure 1A). The administra-
tion of trimetazidine at 3.6 and 7.2 mg/kg 
resulted in 18.2 and 25.8 % increase in 
GSH (3.57 ± 0.22 and 3.80 ± 0.26 vs 3.02 ± 
0.18 µmol/g, p<0.05) (Figure 1B). Mean-
while, the level of nitric oxide decreased by 
45.3, 50.8 and 57.0 % after the administra-
tion of 1.8, 3.6 and 7.2 mg/kg trimetazidine, 
respectively. Values of nitric oxide were: 
26.10 ± 1.60, 23.45 ± 1.80 and 20.50 ± 1.30 
for trimetazidine doses of 1.8, 3.6 and 
7.2 mg/kg, respectively vs lipopolysaccha-
ride control value of 47.70 ± 3.10 µmol/g, 
p<0.05 (Figure 1C).  
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Figure 1B 
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Figure 1C 
 
Figure 1 A-C: Effect of trimetazidine (TMZ) on 
the brain tissue level of (A) malondialdehyde 
(MDA; nmol/g. tissue); (B) reduced glutathione 
(GSH: µmol/g. tissue); (C) nitric oxide (ni-
trite/nitrate; µmol/g. tissue) in lipopolysaccha-
ride-treated mice. Asterisks indicate significant 
change from saline group and between different 
groups as shown. The plus sign indicates sig-
nificant change from the lipopolysaccharide 
control group. One-way analysis of variance 
and Duncan multiple range test for post hoc 
comparison of group means.  
 
Effect of trimetazidine on liver oxidative 
stress 
Liver MDA was increased significantly 
by 107.1 % following lipopolysaccharide 
injection (200 µg/kg, i.p.) (46.10 ± 2.31 vs 
22.26 ± 1.92 nmol/g, p<0.05). The admini-
stration of trimetazidine at 1.8, 3.6 and 
7.2 mg/kg resulted in a significant and dose 
decrease in liver MDA by 18.7, 30.7 and 
49.4 % compared to the lipopolysaccharide 
E control group, respectively. Values of 
MDA were: 37.47 ± 1.18, 31.95 ± 2.10 and 
23.30 ± 1.12 for trimetazidine doses of 1.8, 
3.6 and 7.2 mg/kg, respectively vs lipopoly-
saccharide control value of 46.10 ± 
2.31 nmol/g, p<0.05 (Figure 2A). 
Reduced glutathione was markedly and 
significantly reduced by 84.3 % by admini-
stration of lipopolysaccharide (1.47 ± 0.18 
vs 9.36 ± 0.22 µmol/g, p<0.05). Treatment 
with timetazidine resulted in significant in-
crease in GSH by 150.3 %, 204.8 and 
335.4, respectively (3.68 ± 0.26, 4.48 ± 
0.22 and 6.40 ± 0.28 for trimetazidine doses 
of 1.8, 3.6 and 7.2 mg/kg, respectively vs 
lipopolysaccharide control value of 1.47 ± 
0.18 µmol/g, p<0.05) (Figure 2B). 
Nitric oxide (the level of nitrite/nitrate) 
increased by 48.4 % following lipopolysac-
charide injection (46.90 ± 3.10 vs 31.60 ± 
2.00 µmol/g, p<0.05). The administration 
of trimetazidine at doses of 1.8 or 
3.6 mg/kg did not change liver nitric oxide 
level. However, the level of nitric oxide 
was significantly decreased by 17.3 % 
(p<0.05) by trimetazidine administration at 
7.2 mg/kg vs lipopolysaccharide control 
value (38.80 ± 2.30 vs ± 46.90 ± 3.10 
µmol/g tissue, p<0.05) (Figure 2C). 
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Figure 2C 
Figure 2 A-C: Effect of trimetazidine (TMZ) on 
the liver tissue level of (A) malondialdehyde 
(MDA; nmol/g. tissue); (B) reduced glutathione 
(GSH: µmol/g. tissue); (C) nitric oxide (ni-
trite/nitrate; µmol/g. tissue) in lipopolysaccha-
ride-treated mice. Asterisks indicate significant 
change from saline group and between different 
groups as shown. The plus sign indicates sig-
nificant change from the lipopolysaccharide 
control group. One-way analysis of variance 
and Duncan multiple range test for post hoc 
comparison of group means.  
DISCUSSION 
The present study provided evidence 
that the metabolic modulator and anti-
ischemic agent trimetazidine alleviates oxi-
dative stress caused by lipopolysaccharide 
endotoxin in mice. In both the brain and 
liver, the presence of mild systemic in-
flammatory illness evoked by systemic ad-
ministration of lipopolysaccharide led to 
increased malondialdehyde (MDA) an in-
dex of lipid peroxidation which indicates 
increased free radical production and con-
sequent damage to macromolecules such as 
lipids (Gutteridge, 1995). MDA in the brain 
and liver showed significant decrease by 
trimetazidine treatment, thereby suggesting 
decreased free radicals. Reduced glu-
tathione, an important intracellular antioxi-
dant is also markedly decreased after bacte-
rial endotoxin administration. This thiol is 
common in all tissues and has an important 
role in maintaining the cellular redox bal-
ance and in protection against oxidative in-
jury due to reactive oxygen species (Wang 
and Ballatori, 1998). These findings are in 
line with other studies reporting decreased 
brain GSH, glutathione reductase activity 
and increased lipid peroxidation after single 
intraperitoneal administration of lipopoly-
saccharide in rat and mice (Noble et al., 
2007; Jacewiez et al., 2009). The signifi-
cance of this observation derives from the 
accumulating evidence that links decreased 
GSH to the development of a number of 
neurodegenerative diseases, possibly due to 
consumption by free radicals (Schulz et al., 
2000). In the liver, also, studies indicated 
that reduced glutathione is important in pro-
tecting the liver against toxic injury (Cnub-
ben et al., 2001). The thiol is lower in red 
cells from patients with chronic liver dis-
ease compared with the controls (Czuczejko 
et al., 2003). In both the brain and liver of 
mice given lipopolysaccharide, the admini-
stration of trimetazidine led to marked in-
crease in the level of GSH, thereby, sug-
gesting a beneficial effect for the drug in 
conditions of excessive oxidative stress. 
In the present study, nitric oxide (the 
concentrations of nitrite/nitrate) is also in-
creased in the brain and liver tissue follow-
ing lipopolysaccharide injection. The ad-
ministration of trimetazidine led to marked 
reduction of the elevated nitric oxide in the 
brain and to lesser extent in the liver. Nitric 
oxide is an important signaling molecule in 
biological systems involved in neurotrans-
mission and in control of vascular tone 
(Moncada et al., 1991). Studies indicated 
increased hepatic lipid peroxidation, serum 
liver enzymes and bilirubin in CCl4-treated 
rats (Muriel, 1998) and impaired liver re-
generation (Rai et al., 1998) after inhibition 
of nitric oxide synthase, while increasing 
nitric oxide availability with L-arginine im-
proved hepatic arterial and portal blood 
flow and sinusoidal oxygenation in experi-
mental hepatic steatosis (Ijaz et al. 2005) 
and enhanced regeneration of reduced-size 
livers (Cantré et al., 2008). Increased pro-
duction of nitric oxide can occur in re-
sponse to pro-inflammatory cytokines due 
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to the action of inducible form of nitric acid 
synthase (Moncada et al., 1991). Studies 
indicated the involvement of both inducible 
as well as neuronal nitric oxide in the in-
duction of lipopolysaccharide-induced fever 
(Kozak and Kozak, 2003). The increase in 
nitric oxide levels can be deleterious to tis-
sue functions. In this context, synthesis of 
nitric oxide by both the inducible and con-
stitutive nitric oxide synthase isoforms has 
been shown to contribute to the activation 
of apoptotic pathways in the brain during 
systemic inflammation induced by i.p. 
lipopolysaccharide injection (Czapski et al., 
2007). Nitric oxide is also increased in pa-
tients with chronic liver disease and cirrho-
sis and correlated with disease stage (Arke-
nau et al., 2002; Pârvu et al., 2005). Nitric 
oxide itself is a free radical and can react 
with many other free radicals e.g., superox-
ide radical generating peroxynitrite radical 
capable of causing oxidative changes to 
macromolecules e.g., proteins, lipids and 
DNA (Estévez and Jordán, 2002). Nitric 
oxide also binds to cytochrome c oxidase, 
and is able to inhibit cell respiration in a 
process that is reversible and in competition 
with oxygen. This action can also lead to 
the release of superoxide anion from the 
mitochondrial respiratory chain (Moncada 
and Bolanos, 2006). Thus increased nitric 
oxide and consequent vasodilatation can 
benefit tissue function against toxic insults, 
but another consequence of the elevated 
levels of nitric oxide is its cellular toxicity 
and lipid peroxidation. 
Trimetazidine (2,3,4 trimethoxybenzyl-
piperazine dihydrochloride) is a novel anti-
ischemic compound and a clinically effec-
tive antianginal agent (Stanley and Marzilli, 
2003). It also showed benefit in patients 
with heart failure (Fragasso et al., 2006) 
and in idiopathic dilated cardiomyopathy 
with heart failure (Tuunanen et al., 2008) 
increasing cardiac function and ejection 
fraction. The drug has no vasodilator prop-
erties and has been described as a cytopro-
tective or a cellular anti-ischemic agent 
(Desideri and Celegon, 1998; Belardinelli, 
2000) because it increases cell tolerance to 
ischemia by maintaining cellular homeosta-
sis (McClellan and Plosker, 1999). The 
most widely accepted mechanism of action 
is the inhibition of long-chain 3-ketoacyl 
coenzyme A thiolase (the last enzyme in-
volved in β-oxidation) by trimetazidine. 
This shifts energy substrate preference from 
free fatty-acid metabolism towards glucose 
oxidation, thereby, optimizing energy me-
tabolism (Kantor et al., 2000; Cross, 2001; 
Fragasso et al., 2009). In case of the heart, 
the improvement in cardiac energy metabo-
lism should theoretically translate into en-
hancement in mechanical efficiency 
(Belardinelli, 2000). The drug also im-
proved whole-body insulin sensitivity and 
glucose control in insulin-resistant idio-
pathic dilated cardiomyopathy patients, thus 
hypothetically countering the myocardial 
damage of insulin resistance (Tuunanen et 
al., 2008). Trimetazidine attenuated myo-
cardial reperfusion injury (Castedo et al., 
2005; Khan et al., 2010). In other organs 
such as the kidney (Faure et al., 2004; Jayle 
et al., 2007), trimetazidine displayed cyto-
protective effects as well. Other mecha-
nisms might be also operable in the cyto-
protective action of trimetazidine during 
tissue ischemia such as (1) limitation of the 
intracellular accumulation of protons that is 
responsible for cell acidosis during ische-
mia and also reduced accumulation of Na+ 
and Ca2+ in the cell (Renaud, 1988); (2) 
preservation of the adenosine triphosphate 
pool during reflow (Allibardi et al., 1998); 
(3) inhibition of neutrophil accumulation 
after ischemia and reperfusion (Williams et 
al., 1993); (4) inhibition of thrombin-
induced aggregation and calcium entry into 
platelets (Astarie-Dequeker et al., 1994); 
and (5) antioxidant or free radical scaveng-
ing effect, thereby diminishing the bio-
availability of free radicals and conse-
quently minimizing their toxic effects on 
cellular macromolecules such as membrane 
lipids, proteins and DNA (Guarnieri and 
Muscari, 1993; Bayram et al., 2005). 
Trimetazidine reduced the level of tissue 
malondialdehyde in heart mitochondria 
subjected to oxidative stress (Guarnieri and 
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Muscari, 1993). In ischemia-reperfusion 
injury after lung transplantation, trimeta-
zidine increased adenosine triphosphate 
content, resulted in better oxygenation, and 
reduced lipid peroxidation (Inci et al., 
2001). In rat models of colitis, the elevated 
colonic nitric oxide levels and myeloper-
oxidase activity were reduced by trimeta-
zidine administration (Kuralay et al., 2003), 
whereas total glutathione in tissue is in-
creased by trimetazidine (Girgin et al., 
2000). Trimetazidine given before reflow 
prevented reperfusion-mediated cardiac in-
jury and dysfunction. This protection ap-
pears to be mediated by activation of p38 
mitogen-activated protein kinase and Akt 
signaling (Khan et al., 2010). In a model of 
global myocardial ischemia, trimetazidine 
had a preferential action on the oxidative 
system (mainly on complex I), increasing 
its enzyme activity and decreasing O2 con-
sumption after phosphorylation; this could 
decrease oxygen free radical production and 
increase mitochondrial integrity, thus al-
lowing the maintenance of the electrical 
potential (Monteiro et al., 2004). 
 
CONCLUSION 
In summary, the present study indicates 
that administration of trimetazidine allevi-
ates oxidative stress in the brain and liver 
caused by lipopolysaccharide administra-
tion in mice. It is suggested, therefore, that 
trimetazidine might prove of benefit in 
therapy of systemic inflammation. 
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